BTG3 and myelodysplastic syndrome: In particular, results showed 23.5% (19/81 pts) of ANA positive patients in the MDS group vs 9.4% (5/53 pts; p = 0.0385) in the NHP group and 4.5% (2/44 pts; p = 0.0060) in the HD group, Fig. 2C.